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Edited by Varda RotterAbstract Honokiol, an active component in extracts ofMagno-
lia oﬃcinalis, has been proposed to play a role in anti-inﬂamma-
tory, antioxidant activity, anti-angiogenic and anti-tumor
activity. Although honokiol has a variety of pharmacological
eﬀects on certain cell types, its eﬀects on vascular smooth muscle
cells (VSMC) are unclear. This issue was investigated in the
present study, honokiol was found to inhibit cell viability and
DNA synthesis in cultured VSMC. These inhibitory eﬀects were
associated with G1 cell cycle arrest. Treatment with honokiol
blocks the cell cycle in the G1 phase, down-regulates the expres-
sion of cyclins and CDKs and up-regulates the expression of
p21WAF1, a CDK inhibitor. While honokiol did not up-regulate
p27, it caused an increase in the promoter activity of the
p21WAF1 gene. Immunoblot and deletion analysis of the
p21WAF1 promoter showed that honokiol induced the expres-
sion of p21WAF1 and that this expression was independent of
the p53 pathway. Furthermore, the honokiol-mediated signaling
pathway involved in VSMC growth inhibition was examined.
Among the relevant pathways, honokiol induced a marked acti-
vation of p38 MAP kinase and JNK. The expression of domi-
nant negative p38 MAP kinase and SB203580, a p38 MAP
kinase speciﬁc inhibitor, blocked the expression of honokiol-
dependent p38 MAP kinase and p21WAF1. Consistently, block-
ade of p38 MAPK kinase function reversed honokiol-induced
VSMC proliferation and cell cycle proteins. These data demon-
strate that the p38 MAP kinase pathway participates in
p21WAF1 induction, subsequently leading to a decrease in the
levels of cyclin D1/CDK4 and cyclin E/CDK2 complexes and
honokiol-dependent VSMC growth inhibition. In conclusion,
these ﬁndings concerning the molecular mechanisms of honokiol
in VSMC provides a theoretical basis for clinical approaches to
the use therapeutic agents in treating atherosclerosis.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Vascular smooth muscle cells (VSMC) migrate from the
tunica media to the intima and proliferate to form a neointima*Corresponding author. Fax: +82 43 841 5240.
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doi:10.1016/j.febslet.2006.08.064[1]. These are critical events in the development of atheroscle-
rosis and in restenosis after balloon angioplasty. VSMC in
normal vessels have a very low mitotic rate but begin to prolif-
erate and migrate after exposure to a variety of stimuli, includ-
ing a number of growth factors [2]. Proliferative potential can
be regulated by various signals, blocking growth or inducing
apoptosis [3]. JNK and p38 MAP kinase are known examples
of such stress-activated protein kinases, in as much as they are
strongly activated in response to stressful stimuli. JNK and
p38 MAP kinase have been linked to apoptosis, proliferation
and diﬀerentiation [4–6].
Cell cycle transitions are controlled by the action of cyclin-
dependent kinases (CDKs) and their activating subunits, cyc-
lins [7–9]. VSMC are normally quiescent, proliferate at low
indices (<0.05%), and remain in the G0/G1 phase of the cell cy-
cle [10]. After a vascular injury, VSMC are stimulated to divide
in response to mitogens, and exiting the G1 phase and entering
the S phase. Cyclin D1-CDK4 and cyclin E-CDK2 predomi-
nantly act in sequence during the G1/S transition and are
required for cell cycle progression through this period [11].
The kinase activity of these cyclins/CDK complexes can be
negatively regulated by CDK-inhibitory proteins, including
p21WAF1 and p27 [11,12].
Honokiol, an active component that has been isolated and
puriﬁed fromMagnolia oﬃcinalis extracts, is a commonly used
Chinese medicinal herb, and is reported to have a variety of
pharmacological activities, including anti-inﬂammatory [13],
anti-thrombosis [14], antioxidant eﬀects [15], and to inhibit
NF-kappa B [16]. It can also induce diﬀerentiation in HL-60
human leukemia cells [17]. Moreover, a large number of stud-
ies have demonstrated that apoptosis is induced by honokiol in
diﬀerent cell types, such as human colorectal cells, rat hepatic
stellate cells, and B cell chronic lymphocytic leukemia cells [18–
20]. It has recently been shown that honokiol has both anti-
angiogenic and anti-tumor activity [21]. Although it has been
reported that honokiol inhibits cell growth in diﬀerent cell
types, the precise cellular and molecular mechanisms by which
honokiol inhibits VSMC growth are poorly understood.
In the present study, we explored the mechanism by which
cell growth is inhibited by honokiol in VSMC and examined
the eﬀects of honokiol on cell cycle regulation and MAP kinase
activation in VSMC. The ﬁndings show that the inhibition of
Cyclin D1/CDK4 and Cyclin E/CDK2 activities as the result
of the increased expression of p21WAF1 and the activation
of p38 MAP kinase may be the primary mechanisms by whichblished by Elsevier B.V. All rights reserved.
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strate a link between p38 MAP kinase activation and
p21WAF1 induction, and suggest that p38 MAP kinase is re-
quired for the inhibition of cell growth by honokiol.2. Materials and methods
2.1. Materials
Honokiol was purchased from Wako Chemical Company (Tykyo,
Japan). The drug was dissolved in DMSO with the stock concentration
of 10 mg/ml. Polyclonal antibodies to cyclin E, CDK2, CDK4 was
obtained from Santa Cruz (Santa Cruz, CA). Polyclonal antibodies
to cyclin D1, p21WAF1, p53, p27, p38 MAP kinase, phospho p38
MAP kinase, JNK and phospho JNK were obtained from New Eng-
land Biolabs. Dominant negative p38 MAP kinase was a gift from
Dr. Roger Davis (University of Massachusetts Medical School,
Worcester, MA). SB203580 was obtained from Calbiochem (San Die-
go, CA).
2.2. Cell cultures
Human aortic smooth muscle cells (HASMC) were purchased from
Bio-Whittaker (San Diego, CA) and cultured in smooth muscle cell
growth medium containing 10% FBS, 2 ng/ml of human basic ﬁbro-
blast growth factor, 0.5 ng/ml of human epidermal growth factor,
50 lg/ml of gentamycin, 50 ll/ml of amphotericin-B, and 5 lg/ml of
bovine insulin.
2.3. Cell viability assay
Subconﬂuent, exponentially growing VSMC cells in 24-well plates
were incubated with honokiol for the indicated times. Cell viability
was determined by a modiﬁed 3-(4,5-dimethyl thiazol-2-yl)-2,5-diph-
enyl tetrazolium bromide (MTT) assay, is based on the conversion
of the tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymeth-
oxyphenyl)-2-(4-sulfophenyl)2-Htetrazolium by mitochondrial dehydro-
genase to a formazan product [22], as measured at an absorbance
of 490 nm.
2.4. Cell counts and [3H]-thymidine incorporation
For cell counts, VSMC were plated overnight at equivalent densities
(5 · 105 cells/plate) in 100-mm plates. At intervals after plating, the
cells were trypsinized, and cell numbers were determined using a Coul-
ter Counter. In the case of [3H]thymidine-uptake experiments, VSMC
were grown to near conﬂuence in 24-well tissue culture plates and trea-
ted with honokiol as indicated. The cells were incubated for an addi-
tional 24 h and labeled with [methyl-3H]thymidine (New England
Nuclear; Boston, MA) at a concentration of 1 lCi/ml during the
12 h of this ﬁnal period. After labeling, the cells were washed with
phosphate-buﬀered saline and ﬁxed in cold 10% trichloroacetic acid
and then washed with 95% ethanol. The incorporated [3H]thymidine
was extracted with 0.2 M NaOH and measured in a liquid scintillation
counter as previously described [22]. Values are expressed as the means
from six wells from three separate experiments.
2.5. Cell cycle analysis
Cells were harvested and ﬁxed in 70% ethanol and stored at 20 C.
The cells were then washed twice with ice-cold PBS and incubated with
RNase and DNA intercalating dye propidium iodide, and a cell cycle
phase analysis was performed by ﬂow cytometry using a Becton Dick-
inson Facstar ﬂow cytometer and Becton Dickinson cell ﬁt software.
2.6. Immunoprecipitation and Western blotting
VSMC were treated with honokiol for the speciﬁed periods of time
at 37 C. Cell lysates were prepared, and immunoprecipitation, and
Western blotting were performed as described previously [22].
2.7. Immune complex kinase assays
Cell lysates were prepared with ice-cold lysis buﬀer (containing, in
mM/L, HEPES [pH 7.5] 50, NaCl 150, EDTA 1, EGTA 2.5, DTT 1,
b-glycerophosphate 10, NaF 1, Na3VO4 0.1, and phenylmethylsulfonyl
ﬂuoride 0.1 and 10% glycerol, 0.1% Tween-20, 10 lg/mL of leupeptin,and 2 lg/mL of aprotinin) and sonicated at 4 C (Micro ultrasonic cell
disrupter [from KONTES], 30% power, two times for 10 s each time).
Lysates were clariﬁed by centrifugation at 10000 · g for 5 min, and the
supernatants were precipitated by treatment with protein A-Sepharose
beads precoated with saturating amounts of the indicated antibodies
for 2 h at 4 C. When monoclonal antibodies were used, the protein
A-Sepharose was pretreated with rabbit anti-mouse immunoglobulin
G (Jackson Immuno Research Laboratories). The immunoprecipitated
proteins on the beads were washed four times with 1 mL of lysis buﬀer
and twice with kinase buﬀer (containing, in mM/L, HEPES 50, MgCl2
10, DTT 1, b-glycerophosphate 10, NaF 1, and sodium orthovanadate
0.1). The ﬁnal pellet was resuspended in 25 ll of kinase buﬀer contain-
ing either 1 lg of glutathione S-transferase (GST)-pRb C-terminal
(pRb amino acids 769–921) fusion protein (Santa Cruz Biotechnology)
or 5 lg of histone H1 (Life Technologies Inc.), 20 lM/L ATP, and
5 lCi of [c-32P] ATP (4500 Ci/mmol; ICN), followed by incubation
for 20 min at 30 C with occasional mixing. The reaction was stopped
by the addition of 25 ll of 2· concentrated Laemmli sample buﬀer and
separated on 10% or 12.5% SDS–polyacrylamide gels. The migration
of histone H1 or GST-pRb was determined by Coomassie blue stain-
ing. Phosphorylated pRb and histone H1 were visualized and quanti-
ﬁed with a BAS 2000 bioimaging analyzer.
2.8. Creation of p21WAF1 promoter reporter constructs
The human p21WAF1 promoter construct, WWW-luc
(p21WAF1P), was a gift fromDr. Bert Vogelstein [23]. The preparation
of p21WAF1P D 2.3 has been described previously by Datto et al. [24].
2.9. Transient transfection
Each plasmid was transfected into VSMC using the Superfect re-
agent (Qiagen, Valencia, CA) according to the manufacturer’s instruc-
tions. To assess promoter activity, cells were collected and disrupted by
sonication in lysis buﬀer (25 mM tris–phosphate, pH 7.8, 2 mM
EDTA, 1% Triton X-100, and 10% glycerol). After centrifugation,
the luciferase activity in aliquots was determined using the luciferase
assay system (Promega, Madison, WI) according to the manufacturer’s
instructions. Fireﬂy luciferase activities were standardized for b-galac-
tosidase activity.3. Results
3.1. Inhibition of VSMC growth and DNA synthesis by honokiol
VSMC were grown in 10% FBS containing medium in the
absence or presence of various concentrations of honokiol
(25–150 lM) for 24 h. The eﬀects of honokiol on VSMC
growth and DNA synthesis were investigated. As shown in
Fig. 1A, honokiol signiﬁcantly inhibited cell viability, as evi-
denced by a MTT assay, in a concentration-dependent man-
ner. In addition, the eﬀect of honokiol on cell proliferation
was determined by [3H]-thymidine incorporation after treat-
ment with various concentrations of honokiol for 24 h. As
shown in Fig. 1B, honokiol had a concentration-dependent
inhibitory eﬀect on VSMC growth. Vehicle (DMSO) only
had no eﬀect on the basal levels of cell viability and thymidine
incorporation (Fig. 1A).
3.2. Honokiol induces G1 cell cycle arrest
A ﬂow cytometric analysis (Fig. 2) demonstrated that hon-
okiol (50 lM and 100 lM) induced the accumulation of signif-
icant numbers of cells in the G1 phase of the cell cycle,
suggesting that the observed growth inhibitory eﬀects of hon-
okiol in VSMC were due to cell cycle arrest (Fig. 2).
We next examined the eﬀect of honokiol on cell cycle regu-
latory molecules that are operative in the G1 phase of the cell
cycle. Treatment of VSMC with honokiol at 24 h resulted in a
dose-dependent decrease in the expression of cyclin D1 and cy-
clin E as well as CDK2 and CDK4 (Fig. 3A).
Fig. 1. Eﬀects of honokiol on cell viability and DNA synthesis in
VSMC. (A) Subconﬂuent, exponentially growing VSMC were incu-
bated with honokiol for 24 h at indicated concentrations in 10%
DMEM. Cell viability was determined by a modiﬁed MTT assay.
Results are presented as means ± S.E. from three triplicate experi-
ments. **P < 0.01 compared with no honokiol treatment. (B) Mea-
surement of DNA replication by thymidine uptake as a marker for cell
proliferation. VSMC were grown to near conﬂuence in 24-well tissue
culture plates and treated with honokiol as indicated. Cells were
incubated for an additional 24 h and labeled with [methyl-3H]thymi-
dine at 1 lCi/ml during the last 12 h of this time period. Results are
presented as means ± S.E. from three triplicate experiments. **P < 0.01
compared with no honokiol treatment.
Fig. 2. Honokiol induces G1 cell cycle arrest in VSMC. VSMC were treat
subjected to ﬂow cytometric analysis to determine the eﬀect of honokiol on ce
as the means ± S.E. from three triplicate experiments. Statistical signiﬁcance
of analysis of ANOVA, followed by Fisher’s protected least-signiﬁcant diﬀe
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decrease of kinase activities associated with cyclins
The kinase activities of CDKs are the driving force for the
progression of the cell cycle through the transition check
points, due to their ability to activate cyclins, essential compo-
nents of cyclin–CDK complexes [8,9,11,12]; therefore, we as-
sessed the eﬀects of honokiol treatment on the kinase
activities associated with CDK2 and CDK4 (Fig. 3B). Honok-
iol inhibited the kinase activities of both the CDK2- and
CDK4-immunoprecipitates in a dose-dependent manner at
24 h (Fig. 3B).
3.4. Honokiol-induced cell cycle arrest is associated with the
up-regulation of the CKI, p21WAF1
We next assessed the eﬀect of honokiol on the induction of
p21WAF1, which is known to regulate the entry of cells at
the G1-S phase transition checkpoint [25,26]. An immunoblot
analysis revealed that treatment of VSMC with honokiol re-
sulted in a signiﬁcant dose-dependent induction in p21WAF1
compared with the basal levels (Fig. 4A). Honokiol had no ef-
fect on induction of p27 induced by honokiol. However, under
similar experimental conditions, the levels of expression of p53
tumor suppressor protein were unaﬀected, suggesting that it is
unlikely that p27 and p53 are involved in the cell cycle arrest
induced by honokiol (Fig. 4A).
In honokiol treated cells, the association of CDK2 with
p21WAF1 was maintained at high levels. Levels of
the p21WAF1/CDK4 complexes were also increased in VSMC
at 24 h after honokiol treatment (Fig. 4B). Moreover,
p21WAF1 promoter activity was increased as the result of
honokiol treatment (Fig. 4C). Collectively, these results dem-
onstrate that honokiol induces the expression of p21WAF1
protein and activates its promoter activity.ed with 0 (A), 25 (B), 50 (C), and 100 lM honokiol (D). Cells were
ll cycle distribution. The percentage of cells in each population is shown
represents diﬀerences from control within each experiment with the use
rence (**P < 0.01).
Fig. 3. Eﬀect of honokiol on G1 cell cycle regulator cyclin D1, cyclin
E, CDK2 and CDK4. (A) VSMC were treated with honokiol as
indicated concentration and Western blot analysis was performed with
antibodies speciﬁc for cyclin D1, cyclin E, CDK2 and CDK4. The
results from representative experiments were normalized to GAPDH
expression. (B) VSMC were treated with honokiol at the indicated
concentrations at 24 h, and the cells were then harvested. Total cell
lysates were then immunoprecipitated with anti-CDK2 and anti-
CDK4 antibodies. The kinase reaction was performed using histone
H1 (for CDK2) or GST-Rb (for CDK4) as substrate. The results from
representative experiments were normalized to immunoprecipitated
CDK2 and CDK4 expression. The indicated values are the means of
three triplicate experiments.
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vates p21WAF1 via its interaction with two p53 binding sites
that reside on the p21WAF1P promoter (Fig. 4C) [7,27]. The
deletion mutant p21WAF1PD2.3, which is devoid of p53 bind-
ing sites (Fig. 4C), had no eﬀect on the extent of honokiol
induction relative to basal activity (Fig. 4C). This indicates
that honokiol is capable of inducing p21WAF1, independent
of the p53 pathway. This p21WAF1 promoter activity was in-
creased following the treatment of VSMC with honokiol
(Fig. 4C). In addition, the luciferase activity of the deletion
mutant p21WAF1PD 2.3 remained unchanged, compared to
p21WAF1P (Fig. 4C), suggesting that honokiol induces
p21WAF1 induction in VSMC via a p53-independent path-
way.
3.5. Eﬀects of honokiol on JNK and p38 activation in VSMC
To clarify whether honokiol aﬀects MAP kinase activation,
we examined the eﬀect of various time courses for honokiol on
JNK and p38 activation. Cells were treated with honokiol for
the indicated times. Fig. 5A shows a Western blot analysis of
VSMC treated with honokiol, using antibodies speciﬁc for
phosphorylated JNK and p38 MAP kinase. These experiments
indicate that JNK and p38 MAP kinase are signiﬁcantly acti-
vated by honokiol. Honokiol increased the amount of phos-
phorylated JNK and p38 MAP kinase at 30 min, suggesting
that it induces cell growth inhibition via the activation ofJNK and p38 MAP kinase. This honokiol-induced p38 MAP
kinase activity was blocked by SB203580, a p38 MAP kinase
speciﬁc inhibitor (Fig. 5B). This result indicates that honok-
iol-induced cell growth inhibition signaling likely requires a
p38 MAP kinase mediated pathway.3.6. Honokiol-induced p21WAF1 is blocked by SB203580,
a speciﬁc inhibitor of p38 MAP kinase
p38 MAP kinase has recently been shown to be involved in
the regulation of the cell cycle [22,28] and in the spindle assem-
bly checkpoint and mitotic arrest [29]. Our observations that
p38 MAP kinase activity is induced by honokiol led us to con-
sider whether the p38 MAP kinase activity is related to the
induction of p21WAF1. To elucidate the signal cascade trig-
gered by honokiol, we investigated whether p38 MAP kinase
activity was required for the induction of p21WAF1. Thus,
VSMC were pretreated for 40 min with or without 10 lM
SB203580 or were transfected with the dominant negative
p38 MAP kinase plasmid, followed by exposure to 100 lM
honokiol. As shown in Fig. 5C and D, the honokiol-induced
increase in p21WAF1 expression was reduced to the control le-
vel by SB203580 or dominant negative p38 MAP kinase
expression. These results strongly suggest that p38 MAP
kinase is required in the regulation of p21WAF1 induction
in response to honokiol.3.7. p38 MAP kinase-dependent transcriptional activation
of the p21WAF1 promoter by honokiol
To further elucidate the mechanism of eﬀect of honokiol on
p21WAF1, we examined the expression of the p21WAF1P
promoter in VSMC that had been treated for 24 h with honok-
iol alone or in the presence of SB203580. As shown in Fig. 6A,
honokiol alone had a signiﬁcant stimulatory eﬀect on the
expression of the p21WAF1 promoter, whereas the presence
of SB203580 diminished this eﬀect. To provide additional
and more direct evidence for the role of p38 MAP kinase in
the transcriptional activation of p21WAF1 by honokiol in
VSMC, cells were transfected with p21WAF1P alone or to-
gether with the dominant negative p38 MAP kinase plasmid.
As shown in Fig. 6B, honokiol treatment induced p21WAF1
promoter activity. This activation of p21WAF1 was decreased
in cells that had been transfected with the dominant negative
p38 MAP kinase plasmid. These observations indicate that
honokiol exerts its stimulatory eﬀect on p21WAF1 expression
at the transcriptional level and further supports the view that
this eﬀect is dependent on p38 MAP kinase activity.
3.8. Honokiol-induced cell growth inhibition is reversed by
p38MAPK inhibition
In order to investigate the eﬀect of p38MAPK activation on
honokiol-induced cell growth inhibition, we pretreated the
cells with SB203580, and performed MTT assay, [3H]-thymi-
dine incorporation assay and immunoblot experiments
(Fig. 7A, B, E and F). VSMC were pretreated for 40 min with
or without 10 lM SB203580, followed by treatment with
100 lM honokiol in the presence of 10% serum. As shown in
Fig. 7A and B, the inhibition of cell viability and [3H]-thymi-
dine incorporation by honokiol were reversed by the pretreat-
ment with SB203580. Protein levels of CDK2 and CDK4 were
also reversed after SB203580 treatment for 24 h (Fig. 7E and
F). Similar results were observed using the dominant negative
Fig. 4. Induction of p21WAF1 expression in VSMC by treatment with honokiol. (A) Eﬀect of honokiol on p21WAF1, p27 and p53 expression. (B)
Equal amounts of cell lysates were subjected to immunoprecipitation with anti-CDK2 and anti-CDK4 antibodies. The immunoprecipitates were
examined by SDS–PAGE. After electrophoresis, the samples were transferred to a nitrocellulose membrane, followed by immunoblot analysis with
an anti-p21WAF1 antibody. The results from representative experiments were normalized to immunoprecipitated CDK2 and CDK4 expression. (C)
Stimulation of p21WAF1 promoter activity by honokiol in VSMC. Luciferase activity was determined from cell lysates as described under Section 2.
The indicated values are the means of three triplicate experiments.
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p38MAPK signaling pathway in VSMC was involved in the
cell growth inhibition by honokiol.4. Discussion
Our data show that honokiol treatment induces a rapid
growth arrest in VSMC at 24 h. The results for thymidine
uptake as an index of DNA synthesis in VSMC after honokiol
treatment indicated that DNA synthesis ceases. This is consis-
tent with other’s studies showing that honokiol induces cell
growth inhibition in several cell lines [18–20]. In addition to
the reduced DNA synthesis, cell cycle arrest can easily be over-
looked, especially if propidium iodide staining is used to study
the cell cycle distribution of VSMC in response to honokiol
treatment. The results indicate that honokiol led to G1 cell-
cycle arrest. Our results also showed that treatment of honok-
iol for 24 h resulted in a dramatic increase in the number of
cells in the sub-G1 fraction. The exact mechanism needs to
be elucidated.
Because our studies demonstrated that treatment of VSMC
with honokiol resulted in the G1 phase arrest of the cell cycle
(Fig. 2), we examined the eﬀect of honokiol on cell cycle regu-
latory molecules that are operative in the G1 phase of the cell
cycle. G1 to S cell cycle progression is controlled by several
CDK complexes, including cyclinD1/CDK4 and cyclinE/
CDK2, the activities of which are dependent on the balance
of cyclins and CDK inhibitors (CKIs), such as p27 and
p21WAF1. Our experiment indicated that the treatment of
VSMC with honokiol resulted in the signiﬁcant down-modula-
tion of cyclinD1/CDK4 and cyclinE/CDK2, although to diﬀer-ent extents. Honokiol treatment was found to result in the
dose-dependent inhibition of kinase activities associated with
all of the CDKs examined.
The above data demonstrate that a signiﬁcant up-regulation
in p21WAF1 and CKI occur during the G1-phase arrest of
VSMC by honokiol. Interestingly, however, honokiol had no
eﬀect on the inhibition of p27. Many studies have shown that
the regulation of G1 cell cycle arrest can be attributed to a
number of cellular proteins, including p53 [7]. However, hon-
okiol had no eﬀect on p53 protein levels in VSMC, as deter-
mined by an immunoblot analysis and a promoter assay,
suggesting that the honokiol-induced accumulation of
p21WAF1 independent of the p53 pathway could also be
responsible for the G1 phase arrest. A previous study showed
that honokiol induces G1 cell cycle arrest in HL-60 human leu-
kemia cell diﬀerentiation [17]. Although report has appeared
showing that honokiol induces apoptosis through a p53-inde-
pendent pathway in a human colorectal cell line RKO [18],
to our knowledge, this is the ﬁrst systematic study showing
the involvement of each component of the CKI-cyclin-CDK
machinery during the cell cycle arrest of VSMC induced by
honokiol.
It was recently revealed that the MAP kinase superfamily
plays a crucial role in cell growth, diﬀerentiation, or even pro-
grammed cell death in response to diverse extracellular stimuli
in eukaryotic cells [30,31]. The ﬁndings show that honokiol
treatment resulted in the up-regulation of the JNK and p38
MAP kinase phosphorylation. SB203580, a speciﬁc inhibitor
of p38 MAP kinase, markedly inhibited honokiol-induced
p38 MAP kinase phosphorylation, suggesting that honokiol
induces cell growth inhibition via the activation of p38 MAP
kinase. However, the issue of whether JNK is also associated
Fig. 5. Honokiol-induced p38 MAP kinase phosphorylation is associated with p21WAF1 induction. VSMC were treated for the indicated times with
100 lM honokiol. (A) Cells were harvested, lysed, and the phosphorylations levels of JNK and p38 were detected by immunoblot analysis using
antibodies phosphospeciﬁc for JNK and p38. (B) VSMC were pretreated for 40 min with 10 lM SB203580 before cells were treated with 100 lM
honokiol at 30 min. The results are expressed as mean from three triplicate experiments. **P < 0.01 compared with no honokiol treatment. (C) VSMC
were pretreated for 40 min with the indicated concentrations of SB203580 before stimulating the cells with 100 lM honokiol at 24 h. (D) Cells were
transfected with a dominant negative p38 MAP kinase plasmid and were treated with 100 lM honokiol for 24 h. Proteins were resolved by SDS–
PAGE and immunoblotted with antibodies to p21WAF1. The results are expressed as the means from three triplicate experiments. **P < 0.01
compared with no honokiol treatment.
Fig. 6. p38 MAP kinase-dependent transcriptional activation of
p21WAF1 promoter by honokiol. (A) VSMC were transfected with
the p21WAF1P plasmid and treated with honokiol in the absence or
presence of SB203580. (B) VSMC were transfected with either
p21WAF1P alone, or with the p21WAF1P + dominant negative p38
MAP kinase plasmid and treated with honokiol. The results are
expressed as the means from three triplicate experiments.
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determined.
Previous studies have shown that the MAP kinase pathway
was involved in cell growth inhibition [5] and/or the regulation
of the cell cycle [22,28]. Abundant evidence of the involvement
of p38 MAP kinase in cell growth inhibition currently exists
and is based on the concomitant activation of p38 MAP kinase
and the induction of apoptosis by a variety of agents [5,22,28].
p38 MAP kinase may function both upstream and down-
stream from the signaling cascade of caspases in apoptosis
[32]. p38 MAP kinase signaling has been shown to promote
cell death in some cell lines. It is noteworthy that the role of
p38 MAP kinase in cell growth inhibition is dependent on
the cell type and the stimuli used [33], but its role in VSMC
in response to honokiol is unclear. The ﬁndings herein show
that honokiol induces the phosphorylation of p38 MAP kinase
in VSMC. Since p21WAF1 induction was observed as the re-
sult of honokiol treatment, this prompted us to examine the
role of p38 MAP kinase in the regulation of p21WAF1 expres-
sion. The speciﬁc inhibitor of p38 MAP kinase, SB203580, and
the dominant negative expression of p38 MAP kinase pre-
vented the honokiol-induced p21WAF1 of VSMC, indicating
that honokiol induces p21WAF1 in VSMC through the activa-
tion of p38 MAP kinase. These results are consistent with re-
cent reports that have demonstrated a requirement of the
p38 MAP kinase pathway in agent-induced G1 phase cell cycle
arrest followed by cell growth inhibition [22,34]. Collectively,
the present results suggest that p38MAP kinase is involved
Fig. 7. Inhibition of p38MAPK activity reverses honokiol-induced cell growth inhibition. (A), (B), (E), (F) Cells were plated in plates and were pre-
incubated for 30 min in the absence or presence of 10 lM SB203580. Cells were then treated with 100 lM honokiol. MTT assay, thymidine uptake
and immunoblot experiments were determined as described under Section 2. Indicated values are means of triplicate wells. **P < 0.01 compared with
no honokiol treatment. (C, D) Cells were transfected with a dominant negative p38 MAP kinase plasmid and were treated with 100 lM honokiol for
24 h. MTT assay and thymidine uptake experiments were determined as described under Section 2. Indicated values are means of triplicate wells.
**P < 0.01 compared with no honokiol treatment.
B. Lee et al. / FEBS Letters 580 (2006) 5177–5184 5183in honokiol-induced cell growth inhibition through the induc-
tion of p21WAF1 in VSMC. However, a limitation of our
study is that a clear understanding of relationships between
the activation of JNK pathway and the regulation of
p21WAF1 has not been developed. The exact mechanism
needs to be elucidated.
The eﬀects of honokiol on VSMC proliferation and cell
cycle-associated proteins were conﬁrmed by inhibiting p38
MAPK. Consistent with our observations that honokiol treat-
ment inhibited cell proliferation and modulated cell cycle-asso-
ciated proteins, blockade of p38 MAPK with SB203580 or
dominant negative p38 MAPK vector rescued VSMC prolifer-
ation and cell cycle-associated proteins. These data provide
evidence that p38 MAPK is the important mediator for hon-
okiol-induced VSMC proliferation.
The present study provides some important new sights into
the mechanisms of action of honokiol in VSMC at the molec-
ular level. First of all, they suggest that honokiol reduces cell
viability and cell proliferation. In addition, honokiol arrests
the cell cycle at the G1 phase in VSMC and the honokiol-in-
duced VSMC arrest can be attributed to the inhibition of cy-
clin D1/CDK4 and cyclin E/CDK2 complexes by the
increased expression of p21WAF1 without altering p53 protein
levels. Finally, this honokiol-induced cell growth inhibitionappears to be linked to the activation of p38 MAP kinase
through p21WAF1 expression. The ﬁndings of the present
study may, in part, explain the therapeutic beneﬁts of honokiol
for atherosclerosis or restenosis.
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